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For a decade, sorafenib remained the only approved first-line treatment and standard of care for advanced
hepatocellular carcinoma. The treatment landscape has been evolving rapidly over the past 2 years
with the approval of additional first-and second-line systemic treatments, most of which are targeted
therapies. The expected approval of immunotherapies constitutes a paradigm shift: for the first time in
years, a checkpoint inhibitor in combination with a VEGF antibody recently outperformed sorafenib with
regards to efficacy. The wider availability of systemic therapies increases the chance for longer overall
survival but raises new questions concerning the role of local options, treatment choice and sequential
treatment. Following an expert discussion at the German Cancer Congress 2020 in Berlin, this article aims
to summarize the current evidence on and experience of treatment choice and sequence in first- and
second-line therapy.
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The past 2 years have seen the approval of numerous targeted first- and second-line therapies for advanced
hepatocellular carcinoma (aHCC). Immunotherapeutic concepts are likely to bring about further change in this
therapeutic area. These advances pose challenges in real-world clinical practice in terms of treatment choice and
optimal sequencing. As a follow-up to a meeting of experts at the 2020 German Cancer Conference in Berlin, these
aspects are explored in this article.
For a decade, sorafenib was the only approved first-line treatment and the standard of care in aHCC. However,
the treatment landscape is evolving rapidly. For the first time, the combination of a checkpoint inhibitor and a
VEGF antibody has outperformed sorafenib with regard to efficacy [1].
A wider variety of systemic therapies provides patients with a better chance of survival. At the same time, the
pace of development raises new questions:
1. How will the role of local therapeutic options change?
2. Which first- or second-line therapy is best at the individual patient level, and what is the best treatment sequence?
Given the relative absence of biomarkers in aHCC, real-world treatment choices will have to be informed by
other factors. This article aims to provide an overview of available treatments per line of treatment and to provide
guidance for sequential therapy based on the latest evidence and practical experience.
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Epidemiology & the latest developments
In 2018, almost 23,700 people in Western Europe developed liver cancer (17,300 males and 6400 females) [2], the
most common form of which is hepatocellular carcinoma (HCC). The condition mainly affects males with viral,
metabolic and/or alcohol-induced cirrhosis of the liver. HCC is the fourth most common cause of cancer death
after pulmonary, colorectal and gastroesophageal malignancies [3,4]. The relative 5-year survival rate amounts to
approximately 18%. Annual deaths from liver cancer are projected to reach one million by 2030 [4].
The global incidence of hepatitis-related malignancies has declined over the past 3 decades, whereas a continuous
increase in liver cancer related to nonalcoholic steatohepatitis has been observed during the same period. The latter
trend is probably due to the spread of obesity and diabetes. In Western Europe, the incidence of liver cancer has
doubled from 0.14 to 0.28 per 100,000 in men under 30 years of age and has risen from 0.09 to 0.16 per 100,000
among women of the same age group. A significant increase is also evident among men over 60 [5].
Management of HCC
In recent years, important progress has been made in the treatment of HCC. The prognosis of patients with good
liver function has improved, mainly due to the availability of new systemic therapies and novel sequential treatment
options.
The complexity of HCC demands multidisciplinary patient care, requiring the expertise of (transplantation)
surgeons, pathologists, (interventional) radiologists and hepatologists/oncologists. As of October 2020, there are
22 Cancer Society-certified HCC centers in Germany [6]. As well as having to address the given current situation of
a patient, a therapeutic concept must anticipate potential outcome, including relapses, progression and treatment
failure. The underlying liver condition should be treated wherever possible. Multimodal treatment promises the
best results, but continual review and reappraisal of the treatment strategy is imperative.
Staging-led therapy
70–80% of all cases of HCC are attributable to cirrhosis, which in most cases is accompanied by hepatic impairment.
Complications such as bleeding esophageal varices, ascites and hepatic encephalopathy contribute to high mortality
and morbidity in the patient population. Key risk factors for development of cirrhosis and hence for HCC are [7]
as follows:
• chronic alcohol abuse;
• chronic hepatitis B (HBV) or hepatitis C (HCV) virus infection;
• nonalcoholic steatohepatitis.
Various scores such as the gender, age, alpha fetoprotein L3, alpha fetoprotein, des-carboxy-prothrombin (GALAD)
score have been developed for better assessment of the HCC risk in patients with chronic liver disease. In addition
to the a AFP assay, the GALAD score uses AFP-L3 (lectin-reactive a-fetoprotein) and DCP (des-gamma-carboxy
prothrombin) as parameters [8].
The staging system most commonly used in clinical studies as well as the real world is the Barcelona Clinic
Liver Cancer System (BCLC), which classifies patients into four stages depending on tumor burden, liver function
(Child–Pugh score) and overall health. The pathological diagnosis is based on the tumor–node–metastasis (TNM)
classification and staging according to UICC (Union for International Cancer Control) criteria [9–11].
The European Association for the Study of the Liver (EASL) and European Society for Medical Oncology
(ESMO) recommendations can be consulted for guidance on treatment decisions [9,10] (Figure 1). In addition, the
updated version of the German S3 guideline on the treatment of liver cancer is expected to be published soon.
In addition, over the next years, several clinical trials will mature, investigating the role of systemic therapies such as
neoadjuvant and adjuvant approaches in early stages as well as combinations with transarterial chemoembolization
(TACE) in intermediate stages. Although initial attempts have yielded negative results, the availability of new
treatment options has rekindled hope.
Stage BCLC B: switching from TACE to systemic therapy
TACE is the treatment of choice for tumors confined to the liver, with a maximum diameter of 8 cm and not
more than four nodules in BCLC stage B. Various scores provide assistance in selecting eligible patients. The HAP
(hepatoma arterial-embolization prognostic) score for instance can be used to estimate the likely benefit of TACE
in terms of overall survival (OS) based on liver function and tumor burden [12,13].
10.2217/fon-2020-0758 Future Oncol. (Epub ahead of print) future science group
Systemic therapy of advanced hepatocellular carcinoma Review
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Figure 1. Treatment algorithm by European Society for Clinical Oncology.
BCLC: Barcelona Clinic Liver Cancer; BSC: Best supportive care; EMA: European Medicines Agency; HCC: Hepatocellular carcinoma; LTX:
Liver transplantation; MCBS: ESMO-Magnitude of Clinical Benefit Scale; SBRT: Stereotactic body radiotherapy; SIRT: Selective internal
radiotherapy; TACE: Transarterial chemoembolisation.
Modified based on [10].
TACE was established 20 years ago at a time when there was no alternative for people with advanced tumors. In
the absence of effective systemic treatment options, this resulted in TACE increasingly being used in patients for
whom it was not necessarily suited. However, because effective systemic therapies are now available, it is time to
revisit TACE’s role, especially as it may be linked to impairment of liver function. To complicate matters, several
different techniques are available, and the role of cytotoxic drugs is controversial [14].
In addition to rigorous selection of patients for TACE, another important factor is the appropriate time to
discontinue local therapies. Both treatment response to TACE and deterioration of liver function are key decision-
making criteria: patients with no objective response to treatment after the second TACE have a significantly shorter
OS than patients who achieve deep remission. Hence, scrutiny should be exercised before readministering TACE,
particularly beyond a second administration [15].
The decision of when TACE therapy should be interrupted is complex. In recent years, several scores have
been proposed to guide the retreatment decision (e.g., assessment for retreatment [ART] score with TACE) [16].
According to the EASL guidelines, “their applicability is controversial and such scoring systems probably identify
patients who were poor candidates for TACE at baseline, as defined in these guidelines” [9].
Stage BCLC B–C: systemic therapy
First-line treatment
Sorafenib
Sorafenib was the first targeted therapy to show efficacy in patients with aHCC. This multitarget tyrosine kinase
inhibitor (TKI) targets VEGF receptor, PDGF receptor, RAF and several other tyrosine kinases. On the basis of a
double-blind randomized controlled clinical trial (SHARP; n = 602) and the Asia-Pacific study, sorafenib was the
undisputed standard of care in advanced stages for a decade.
The pivotal trial was conducted mainly in European patients (87.5%), approximately one-third of whom had
HCC related to hepatitis C. More than half had an Eastern Cooperative Oncology Group performance score
(ECOG-PS) score of 0 (54%), almost all had good liver function (Child–Pugh A) and more than 80% were in
BCLC stage C. Approximately half of the patient population had extrahepatic metastasis (EHD) and 70% had
microvascular invasion (MVI) [17].
Sorafenib treatment significantly extended the mOS of patients in comparison with placebo (10.7 vs 7.9 months;
HR = 0.69; 95% CI: 0.55–0.87; p < 0.001). Sorafenib treatment benefit was furthermore unrelated to ECOG-PS,
MVI or EHD status. The objective response rate (ORR) was low (2%) [17]. Similar results were reported in the
Phase III Asia-Pacific study conducted mainly in patients with hepatitis B [18].
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Clinical factors predictive of better sorafenib response include chronic hepatitis C infection, a low neutrophil to
lymphocyte ratio and liver-confined disease [19,20].
Analysis of GIDEON, a prospective registry study in 3202 patients, suggested that sorafenib could be used to
treat Child–Pugh B HCC with no major increase in side effects. However, given the poorer prognosis of patients
and in the absence of a proven survival benefit from sorafenib treatment, caution should be exercised when using
the TKI to treat individuals with uncompensated cirrhosis [21,22].
The PROSASH score can be used to predict the OS of a patient treated with sorafenib: it considers vascular
invasion, age, ECOG-PS, alkaline phosphatase (AP), albumin, creatinine, AST, extrahepatic metastasis and the
etiology. An associated online tool calculates the likely OS rate at 6, 12, 24 and 36 months [23,24].
Lenvatinib
After multiple failed studies, lenvatinib was the first drug to show noninferiority to sorafenib with regard to OS
(primary end point) in the randomized, open-label, Phase 3 REFLECT trial in 2017. Importantly, this multitarget
TKI inhibits FGF receptor, KIT and RET as well as VEGF and PDGF receptor. The study was conducted mainly
in Asian patients, all of whom had good liver function (Child–Pugh A); 79% of participants had BCLC stage C
disease. In addition, the majority of participants had an ECOG-PS score of 0 (63%), approximately 60% had
EHD and about 20% had MVI (with portal vein invasion at the main portal branch and more than 50% liver
involvement being exclusion criteria). AFP levels were below 200 ng/ml in 57% of patients [25].
Although lenvatinib was statistically noninferior to sorafenib with regard to OS (13.6 vs 12.3 months; hazard
ratio [HR]: 0.92; 95% CI: 0.79–1.06; upper boundary for noninferiority set at 1.08; noninferiority observed
across all subgroups). In contrast to the OS results, the TKI was significantly superior to sorafenib with regard to
key secondary end points. Investigator-assessed median progression-free survival (PFS) as measured by mRECIST
criteria was extended from 3.7 to 7.4 months under lenvatinib (HR: 0.66; 95% CI: 0.57–0.77; p < 0.0001). Time
to progression (TTP) was 7.4 vs 3.7 months. In nominal terms, these results were consistently better than in the
sorafenib SHARP trial, which, however, was not a global study and was mainly conducted in Asian patients [25].
Lenvatinib also significantly outperformed sorafenib in terms of ORR (24.1% vs 9.2%; odds ratio [OR]: 3.13;
95% CI: 2.15–4.56; p < 0.0001). This benefit was confirmed by independent review based both on mRECIST
and RECIST 1.1 criteria [25].
The most common all-grade adverse events (AEs) included hypertension (42%), diarrhea (39%), reduced appetite
(34%) and weight loss (31%) in the lenvatinib arm and hand–foot syndrome (52%), diarrhea (46%), hypertension
(30%) and loss of appetite (27%) in the sorafenib arm. At 75% and 67%, respectively, the incidence of grade ≥3
AEs was similar in both arms, with hypertension (lenvatinib vs sorafenib: 23% vs 14%), diarrhea (4% in each arm),
reduced appetite (5% vs 1%) and weight loss (8% vs 3%) predominating. Patients receiving lenvatinib benefited
from a significantly lower incidence of hand–foot syndrome (3% vs 11%); 9% vs 7% of patients discontinued the
study due to treatment-emergent AEs [25].
Patient health-related quality of life (HRQoL) worsened in both arms; however, HRQoL deterioration due to
symptoms such as pain and diarrhea was less pronounced in patients receiving lenvatinib than in patients receiving
sorafenib [26].
For the first time, a retrospective analysis of the REFLECT study enabled investigation of the relevance of treat-
ment response during systemic therapy in a large patient population. Patients achieving partial or complete response
during treatment (lenvatinib, n = 115 and sorafenib, n = 44) had an mOS of 22.4 months, whereas nonresponders
had an mOS of 11.4 months (HR = 0.61; 95% CI: 0.49–0.76). Importantly, these results confirmed observations
that had previously been made in small patient populations only [27,28].
Liver function status at baseline is a well-described prognostic factor. However, a post hoc analysis of the
REFLECT trial showed that in the lenvatinib arm even patients with poor liver function at baseline benefited
versus sorafenib [29].
Atezolizumab + bevacizumab
The IMbrave150 study was the first study in which sorafenib was outperformed in terms of OS. The atezolizumab–
bevacizumab combination addresses both (re)activation of immune response to tumor cells and angiogenesis.
Preclinical data furthermore indicate that bevacizumab is not only antiangiogenic but also immunomodulatory in
its effects in that it reduces VEGF-mediated immunosuppression and improves cancer immunity [30].
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Figure 2. Overall and progression-free survival in the IMbrave150 study.
Mo: Months; NE: Not evaluable.
Modified based on [1].
Initial headline data of a randomized, open-label Phase III trial were presented at ESMO Asia 2019. The anti-
VEGF checkpoint inhibitor (CPI) combination was compared to sorafenib in patients with locally advanced or
metastatic HCC (n = 501). Only patients with Child–Pugh A cirrhosis were eligible to participate: 81.5% had
BCLC stage C disease, 62% had an ECOG-PS score of 0 and 75% had EHD and/or MVI; 62% of participants had
AFP levels below 400 ng/ml. HCC patients with autoimmune diseases or immunodeficiency, immunomodulatory
therapy, chronic NSAID use, concomitant hepatitis B or C infection or untreated esophageal varices within
6 months before treatment initiation were excluded from the trial. Coprimary end points were OS and PFS [1].
After a median follow-up of 8.6 months, median OS had not yet been reached in the atezolizumab–bevacizumab
arm, whereas in patients receiving sorafenib, median OS was 13.2 months (HR: 0.58; 95% CI: 0.42–0.79,
p < 0,001). Furthermore, participants treated with the combination remained progression-free for a median
of 6.8 months, compared with 4.3 months in the sorafenib arm (HR: 0.59; 95% CI: 0.47–0.76; p < 0.001)
(Figure 2) [1].
In this very early analysis with only a small number of events, OS and PFS results were consistent across most of
the investigated subgroups; however, the final analysis is yet to be published [1].
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Figure 3. Tolerability in the IMbrave150 study.
AE: Adverse event; Atezo: Atezolizumab; Bev: Bevacizumab; PPE: Palmar-plantar erythrodysesthesia syndrome.
Modified based on [1].
More than twice as many patients in the interventional arm responded to therapy (ORR as per independent
review using RECIST 1.1 criteria: 27% vs 12%, p < 0.0001; ORR as per mRECIST: 33% vs 13%, p < 0.0001).
18 patients (6%) receiving atezolizumab plus bevacizumab achieved complete response and 71 (22%) achieved
partial response, compared with 0 and 19, respectively, receiving sorafenib (12%) [1].
Both all-grade AEs and grade 3–4 AEs were similar in both arms, however, treatment in the combination arm
went on for considerably longer and the nature of side effects was very different. With regards to the side effects
shown in Figure 3, the combination therapy was tolerated significantly better compared with sorafenib. In the
atezolizumab–bevacizumab arm, the most common side effect was hypertension; 16% of patients discontinued
treatment with either agent and 7% discontinued treatment altogether. In comparison, 10% of patients receiving
sorafenib discontinued treatment due to side effects [1].
To minimize the bleeding risk from bevacizumab, esophageal varices were treated before the initiation of therapy.
The incidence of bleeding amounted to approximately 20% in both arms and was therefore manageable [1].
The combination also outperformed sorafenib with regard to patient-reported outcomes. At the 2020 Gastroin-
testinal Cancers Symposium, a prespecified analysis of the IMbrave 150 study showed that clinically meaningful
worsening of overall patient HRQoL (11.2 vs 3.6 months; as measured by the EORTC QLQ-C30 questionnaire),
role functioning and physical functioning was slower in patients receiving atezolizumab plus bevacizumab and that
key symptoms occurred later. In addition, symptoms such as loss of appetite, diarrhea, fatigue, jaundice and pain
were less common in the combination arm [31].
Nivolumab
Single-agent CPIs have not significantly prolonged OS in aHCC to date. The Phase III CheckMate 459 study only
showed a trend in favor of nivolumab in terms of mOS extension versus sorafenib (16.4 vs 14.7 months, HR: 0.85;
95% CI: 0.72–1.02; p = 0.0752). Importantly, however, mOS exceeded 14 months in both arms – a significant
achievement for this indication. Nivolumab furthermore doubled the ORR in comparison with sorafenib (15% vs
7%) [32].
First-line treatment decisions
All three first-line therapies (data summarized in Table 1) were evaluated predominantly in patients with good
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Table 1. Selected study results of first-line therapies in advanced hepatocellular carcinoma.
End point Atezolizumab + bevacizumab vs
sorafenib
(n = 501)†
Lenvatinib vs sorafenib
(n = 954)‡
Sorafenib vs placebo
(n = 602)§
OS (median, months),
[HR; p-value]
NA vs 13.2
[0.58; 0.0006]
13.6 vs 12.3
[0.92; not inferior]
10.7 vs 7.9
[0.69; 0.001]
PFS (median, months)
[HR; p-value]
6.8 vs 4.3
[0.59; 0.001]
7.4 vs 3.7
[0.66; 0.0001]
Not studied
ORR (%) 27.3 vs 11.9 24.1 vs 9.2
CR 5.5 vs 0 1 vs 1 0 vs 0
PR 21.8 vs 11.9 23 vs 9 2 vs 1
SD 46.3 vs 43.4 51 vs 51 71 vs 67
Duration of response (median,
months)
NA vs 6.3
CR: Complete response; NA: Not achieved; ORR: Overall response rate; OS: Overall survival, PFS: Progression-free survival; PR: Partial response; SD: Stable disease.
†Data taken from [1].
‡Data taken from [25].
§Data taken from [17].
overall health and good liver function, the majority of whom had BCLC stage C disease [1,17,25]. The REFLECT
study had the largest proportion of Asian participants (approx. 70%) [24]. Regardless of the treatment choice, blood
pressure should be managed at initiation or adjusted during treatment if necessary. Liver function status is essential
in determining whether patients are eligible for systemic first-line therapy. On the basis of the studies performed,
all patients with Child–Pugh A cirrhosis are eligible.
For the first time in more than a decade, the anti-VEGF-checkpoint inhibitor combination significantly prolonged
OS in aHCC versus sorafenib. The ORR of 27% might deliver additional benefit in particular to patients with
a high tumor burden. Moreover, the combination is considerably less toxic and has less of an impact on patient
HRQoL [30]. This is why experts believe approval of the atezolizumab–bevacizumab combination will establish a
new standard of care in first-line treatment of this indication.
Given the exclusion criteria in the IMbrave150 study and the mechanism of action underlying immunotherapy,
aHCC patients with autoimmune diseases should not receive atezolizumab + bevacizumab. The same is true for
patients whose aHCC has relapsed after a liver transplant. To reduce the bleeding risk, eligible patients should
undergo endoscopic staging of esophageal varices before initiation of treatment. Appropriate therapy is required
before initiating treatment in individuals with clinically significant varices (grade ≥2) [33].
Combination therapy is administered by infusion every 3 weeks. While encouraging good adherence, this means
patients need to be sufficiently mobile.
Therapy with a CPI requires careful, long-term patient monitoring, given the risk of potential immune-related
side effects because these may occur even after the discontinuation of treatment [34]. Continuous monitoring
of laboratory findings – in particular, monitoring of liver function and glucose levels – is recommended during
treatment. Close monitoring for potential proteinuria is also advised.
Sorafenib and lenvatinib monotherapies are alternative treatment options where the combination therapy with
atezolizumab + bevacizumab is contraindicated. Both drugs are taken orally either once (lenvatinib) or twice a day
(sorafenib). This is convenient for patients but also gives them sole responsibility for adherence. Before starting
TKIs, careful weighing of the risks as well as benefits is required in individuals with a history of aortic aneurysm.
Concomitant use of CYP3A4 inducers should be avoided during therapy [35,36].
Favorable data on the secondary end points PFS, TTP and ORR may be clinically relevant and an argument for
the use of lenvatinib. The ORR of 24% observed in the REFLECT trial might be advantageous in certain situations
– for instance, if a tumor site in the hepatic hilum is interfering with liver function. However, it is also important
to be aware that patients with very advanced disease, including tumor occupation of more than half of the liver,
were excluded from the pivotal trial, as were individuals with portal vein invasion at the main portal branch [25].
There are a number of indications demonstrating that lenvatinib may be associated with an increased incidence
of hepatic encephalopathy in patients with major portal hypertension. Patients should therefore be informed
accordingly [36].
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Table 2. Target structures of tyrosine kinase inhibitor/antibodies approved for advanced hepatocellular carcinoma.
Line Drug VEGF PDGFR RAF FGFR KIT RET TIE-2 MET AXL
1st Sorafenib TKI X X x
1st Lenvatinib TKI X X X X X
2nd Regorafenib TKI X X X X X X
2nd Cabozantinib TKI X X X
2nd Ramucirumab TKI X
mAB: Monoclonal antibody; TKI: Tyrosine kinase inhibtor.
Many years of experience with sorafenib have ultimately resulted in optimization of treatment. Noninterventional
trials such as the Gideon trial have improved our understanding of side effects and efficacy [21]. Preemptive therapy
of hand–foot–skin reactions and monitoring during treatment for the onset of hypoglycemia and bleeding are of
great importance [35].
Gastrointestinal problems, mainly diarrhea, can occur with both TKIs [17,25]. Data from a post hoc analysis of the
REFLECT trial indicate that certain side effects such as hypertension, diarrhea, proteinuria and hypothyroidism
during lenvatinib therapy were associated with a longer OS [37]. Similar data exist for sorafenib, where it has been
suggested that hand–foot syndrome may also be an indicator of a better OS. Onset of hypertension in the first
2 weeks of sorafenib treatment has furthermore been associated with a better PFS and onset of diarrhea seems to
be predictive of a good response to sorafenib [38,39].
Effective side effect management is important for successful treatment, irrespective of the line of treatment. Skin
toxicities, hypertension and diarrhea in particular need to be addressed proactively as part of the treatment concept
in multitarget TKI therapy. On the basis of observations to date, dose reductions do not seem to have a negative
impact on OS during treatment with sorafenib [40]. Very close monitoring of patients with cardiac impairments is
imperative during treatment with both TKIs and bevacizumab.
Second-line treatment
Three drugs are currently approved for the second-line treatment of aHCC; these have previously shown benefits
in patients pretreated with sorafenib in placebo-controlled trials. Again, only patients with good liver function
(Child–Pugh A) and good ECOG-PS (0–1) were enrolled. Regorafenib and cabozantinib are TKIs that primarily
target VEGF receptors but also have other target structures; ramucirumab is a monoclonal antibody directed against
VEGFR-2 (Table 2 based on [35,36,41–43]).
Regorafenib
Regorafenib target structures in addition to VEGFR include PDGFR, RAF, FGFR, RET, KIT, TIE-2 and others.
This multitarget TKI was evaluated in the randomized, double-blind, placebo-controlled, Phase III trial RESORCE
(n = 573). Inclusion criteria comprised intact liver function (Child–Pugh A) and progression on adequately tolerated
prior sorafenib treatment. More than 60% of patients had an ECOG-PS of 0; more than 80% had MVI or EHD,
44% had AFP levels of ≥400 ng/ml and 87% of participants had BCLC stage C disease [44].
Regorafenib treatment resulted in a significant extension of the mOS relative to placebo from 7.8 to 10.6 months
(primary end point; HR: 0.63; 95% CI: 0.50–0.79; p < 0.0001). Median PFS as measured by mRECIST criteria
was 3.1 versus 1.5 months (HR: 0.46; 95% CI: 0.37–0.56; p < 0.0001). TTP was also significantly prolonged
in favor of regorafenib (3.2 vs 1.5 months; HR: 0.44; 95% CI: 0.36–0.55; p < 0.001). The ORR was 10.6%
versus 4.1% (p = 0.005), and the tumor control rate amounted to 65.2% versus 36.1% (p = 0.001). An efficacy
benefit was observed in all subgroups [44].
The most common grade 3–4 AEs in the intervention arm were hypertension (15%), hand–foot syndrome
(13%), fatigue (9%) and diarrhea (3%). One in ten patients in the intervention arm and 4% in the placebo arm
discontinued treatment due to side effects. The most common reasons for treatment discontinuation were hand–
foot syndrome and increased aminotransferase levels. Similar to first-line sorafenib, the occurrence of hand–foot
syndrome while receiving regorafenib correlated with a better OS [45].
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Cabozantinib
Cabozantinib does not only inhibit VEGF receptor, RET, KIT and FLT3 but also Tyro3, Mer, MET and AXL,
which have previously been associated with resistance to sorafenib [46]. The multitarget TKI was evaluated in
the randomized, double-blind, placebo controlled, Phase III trial CELESTIAL in patients with progression of
unresectable HCC following at least one prior systemic treatment with sorafenib (n = 707). Three-quarters
of patients were non-Asian, 53.5% had an ECOG-PS of 0, 78% had EHP and approximately one-third had
MVI (84.5% had both). Cabozantinib was the third line of systemic treatment for about one-quarter of the
participants [47].
Cabozantinib significantly extended mOS versus placebo (primary end point; 10.2 vs 8.0 months HR: 0.76;
95% CI: 0.63–0.92; p = 0.005) and significantly improved PFS as well (secondary end point; median 5.4 vs
1.9 months; HR: 0.44; 95% CI: 0.36–0.52; p < 0.001). The ORR as measured by RECIST 1.1 criteria was 4%
versus 0.4%. Furthermore, the disease control rate (DCR) was 64% in patients receiving cabozantinib – almost
twice as high as in the placebo arm (33.4%; p < 0.001) [47].
Data from a post hoc analysis indicate that the OS benefit was greater the earlier patients received cabozantinib
(second line vs later lines: 11.3 vs 7.2 months; HR: 0.70; 95% CI: 0.55–0.88) [47]. An additional analysis of the
CELESTIAL study produced similar results; here, cabozantinib was efficacious irrespective of ALBI (albumin-
bilirubin) grades. Median OS was 17.5 months in patients with ALBI grade 1 versus 8.0 months in patients with
ALBI grade 2; however, this analysis was not set up to compare efficacy in subgroups stratified by ALBI grade [48].
Time on previous treatment (with sorafenib) had no effect on either OS or PFS in the cabozantinib arm [47].
Grade 3–4 side effects occurred in 68% of patients treated with cabozantinib, the main toxicities being hand–foot
syndrome (17% vs 0%), hypertension (12% vs 2%), AST level elevation (12% vs 7%), fatigue (10% vs 4%) and
diarrhea (10% vs 2%). The most common reasons for treatment discontinuation (16%) were hand–foot syndrome,
fatigue and gastrointestinal problems [47].
Quality-adjusted time without symptoms and toxicity (Q-TWiST) was measured in a retrospective analysis [49].
This method enables an assessment of the benefit–risk ratio of a treatment in the absence of HRQoL data: the
relationship between survival benefit and HRQoL being the main interest [50]. Three factors were analyzed: time
with grade 3/4 toxicity before progression (TOX), time without grade 3/4 toxicity before progression (TWiST) and
survival time after progression or relapse (REL). The analysis showed that patients with aHCC receiving second-
line cabozantinib after sorafenib spent significantly more time without disease symptoms and toxicity than those
receiving placebo (110.9 vs 78.1 days), despite an increase in days with grade 3/4 toxicity before progression (49.8
vs 9.8 days) [49].
Ramucirumab
Ramucirumab is a monoclonal antibody that is directed against VEGFR-2 and administered by infusion. In the
randomized Phase III trial REACH-2 it was compared with placebo in patients whose disease had progressed on or
who were unable to tolerate sorafenib. Participants were required to have an unfavorable prognosis as characterized
by AFP levels ≥400 ng/mL. Approximately one-third of patients had MIV and about three-quarters had EHD [51].
Median OS was 8.5 versus 7.3 months favoring ramucirumab (primary end point; HR: 0.71; 95% CI: 0.53–0.95;
p = 0.0199). The antibody also significantly extended median PFS (secondary end point; 2.8 vs 1.6 months; HR:
0.452; 95% CI: 0.40–0.60; p < 0.0001) [51]. Pooled analysis of REACH-1 and REACH-2 study data confirmed
the OS benefit for ramucirumab (8.1 vs 5.0 months; HR: 0.69; 95% CI: 0.57–0.84; p = 0.0002) [52].
Ramucirumab had a more favorable tolerability profile than the TKIs. With regard to grade ≥3 AEs, only
hypertension (13% vs 5%), hyponatremia (6% vs 0%) and increased aspartate aminotransferase (3% vs 5%) were
more common in the intervention arm than in the placebo arm [51]. Furthermore, pooled analysis of patient-level
data from the REACH-1 and REACH-2 studies (same inclusion criteria with AFP levels ≥400 ng/mL, same study
design) showed that symptoms such as nausea, fatigue and weight loss worsened later than on placebo [52].
A post hoc analysis indicated that liver function correlated with OS in the ramucirumab arm. Patients with
ALBI grade 1 lived considerably longer than those with ALBI grade 2 (ramucirumab: 11.4 vs 5.8; placebo: 6.6 vs
4.2 months). Furthermore, a trend toward a better response to ramucirumab was observed in patients with intact
liver function [53].
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Figure 4. Indirect comparison of patient data listings from Phase III studies of cabozantinib and regorafenib in
advanced hepatocellular carcinoma (second line).
Modified based on [55].
Sorafenib
Sorafenib is approved for the treatment of HCC across BCLC stages and treatment lines [35], which may be
relevant for sequential treatment and reimbursement. Importantly, second-line efficacy has never been formally
demonstrated.
Second-line treatment decisions
As in the first line, the primary goal of second-line aHCC treatment is the extension of OS while maintaining patient
quality of life. Unlike in the first line, however, no head-to-head studies evaluating the different treatment options
exist; all three agents have been compared with placebo only. Regorafenib and cabozantinib are oral therapies,
whereas ramucirumab is administered intravenously.
Several parameters for treatment decision-making have emerged from the pivotal trials. Regorafenib is approved
for all HCC patients who have previously received sorafenib [41]. However, the TKI has only ever been studied in
patients who had tolerated a prior 4-week therapy with ≥400 mg sorafenib [52]. Regorafenib’s benefit was unrelated
to baseline AFP levels [54].
Regorafenib is an oral therapy comprising four tablets once a day for 3 weeks followed by a 1-week break. Tablets
are ingested after a light meal (<600 calories and <30% fat) [41].
Cabozantinib has been studied in patients whose prior sorafenib treatment was discontinued either because of
disease progression or because of intolerable toxicity [47].
Results of an indirect comparison of patient-level data from Phase III studies suggest that median PFS may be
significantly longer with second-line cabozantinib than with second-line regorafenib (5.6 vs 3.2 months; 95% CI:
4.90–7.26; p < 0.05). mOS was not significantly longer (11.4 vs 10.8 months; Figure 4) [55]. It should be noted,
however, that interstudy comparisons of disparate studies have various weaknesses.
In comparison with placebo, cabozantinib improved outcomes across a range of baseline AFP levels. AFP response
and control rates were higher with cabozantinib than with placebo and were associated with longer OS and PFS [56].
Cabozantinib’s efficacy as a second-line treatment was not dependent on the duration of the previous sorafenib
therapy; however, the OS tended to be longer if sorafenib had been administered over extended periods of time (up
to 6 months) [47].
In the CELESTIAL trial, the incidence of side effects was high, resulting in cabozantinib dose reductions or
treatment discontinuation [47]. However, patient HRQoL in the cabozantinib arm was similar to that observed in
the placebo arm [49].
Cabozantinib is taken once a day as a tablet [42].
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Figure 5. Overall survival of patients receiving sorafenib followed by regorafenib (exploratory analysis).
Modified based on [59], reprinted with permission from Clinical Care Options Oncology. Available at
www.clinicaloptions.com.
The REACH-2 trial is the first positive biomarker-driven study in aHCC, which is also reflected in the label:
ramucirumab treatment is restricted to HCC patients who have been previously treated with sorafenib and who
have a serum AFP level of ≥400 ng/ml [43]. The etiology of the condition (HBV vs HCV) does not seem to have
an effect on response [57].
Ramucirumab is administered by intravenous infusion every 2 weeks. The dose is based on body weight [43].
Biomarkers
In terms of its clinical and molecular features, HCC is a very heterogeneous condition, which is why predictive
biomarkers – other than AFP level for second-line ramucirumab – have not been identified to date. The influence
of PD-L1 expression on response to checkpoint inhibitor therapy has not been clarified to date.
Sequential treatment
Sequential treatment offers patients with aHCC a chance of improved long-term survival. Exploratory and post hoc
analyses indicate that sequential administration of the available first- and second-line monotherapies can result in
an OS of about 2 years [58,59]. We can expect survival to improve even further with immunotherapy combinations.
Because all currently available second-line treatments have only ever been tested in patients progressing on or
becoming intolerant to prior sorafenib, evidence for the efficacy of second-line treatment options administered
after prior lenvatinib is unavailable. A post hoc analysis of the REFLECT study demonstrated an OS of 20.8 months
in patients who received another systemic therapy after first-line lenvatinib, the most common of which was
second-line sorafenib [58].
In a post hoc analysis of the RESORCE trial, the OS of patients receiving sorafenib prior to regorafenib was
26 months (Figure 5). Interestingly, the OS benefit observed with second-line regorafenib did not correlate with
the time to progression on first-line sorafenib [59].
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We expect that, once approved, the combination of atezolizumab and bevacizumab will become the new standard
of care in first-line therapy. As a consequence, the future status of sorafenib and lenvatinib as well as their position
in a potential treatment algorithm are currently uncertain.
At present, no data exist on the treatment sequencing in this setting. It would make sense to administer the most
efficacious current first-line treatment option (lenvatinib) after failure of first-line atezolizumab + bevacizumab;
yet, for the time being, the product labels would only allow for the use of sorafenib in the second line.
In the US, nivolumab and pembrolizumab as well as the combination of ipilimumab plus nivolumab have
received accelerated US FDA approval in second-line aHCC – however, these options are thus far not available in
Europe [60–62].
Future perspective
The pending approval of immunotherapies will change the treatment of aHCC profoundly. In addition, we
now have various drugs at our disposal that can significantly prolong patient survival, giving us the opportunity to
sequentially apply systemic treatments. In view of further first-line studies investigating immunotherapeutic combi-
nations (e.g., PD-L1-Inhibitor + CTLA4 antibodies: durvalumab plus tremelimumab; HIMALAYA; TKI + PD-1
inhibitor: lenvatinib plus pembrolizumab; TKI + PD-L1 inhibitor: cabozantinib plus atezolizumab; COSMIC-
312), identifying the optimal treatment sequence will become increasingly relevant for clinical practice [63–65]. It
would be useful to establish clinical features or reliable predictive biomarkers, which could then help to detect
patients benefitting the most from the different systemic treatment options. Moreover, we need to promote our
knowledge of the development of resistance mechanisms; this will be the key to implementing more personalized
approaches in aHCC therapy. The results of several Phase III trials of neoadjuvant and adjuvant immunotherapies
(e.g. IMbrave050, CheckMate 9DX and KEYNOTE-937) will further add to the complexity of sequential therapy.
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Executive summary
Transarterial chemoembolization
• Despite major advances in systemic therapies, local options remain an integral part of the treatment of
hepatocellular carcinoma (HCC) patients in Barcelona Clinic Liver Cancer System (BCLC) stage B.
• Selecting patients for TACE requires multidisciplinary discussion in a tumor board setting.
• The ideal candidate will have good liver function (ideally albumin-bilirubin [ALBI] grade 1), and one to four
tumors measuring not more than 3 to 8 cm (or larger if singular tumors are involved). Liver function should not
deteriorate under TACE.
• Switching to systemic therapy should be considered after the second application in the event of poor tolerability,
deterioration of liver function or lack of response to TACE.
First-line treatment
• Patients who are not candidates for resection or locoregional therapy, whose liver function is intact (Child–Pugh
A) and who are in good overall health (ECOG-PS 0–1) should receive systemic therapy.
• Intravenous treatment with atezolizumab + bevacizumab will establish itself after approval as the new standard
of care in systemic first-line therapy.
• Potential contraindications need to be ruled out before initiating combined immunotherapy and
antiangiogenesis; esophageal varices and autoimmune diseases in particular.
• Sorafenib and lenvatinib monotherapies are available as alternatives for individuals with contraindications to
combination therapy. Oral tyrosine kinase inhibitor (TKI) therapies have somewhat different vascular target
structures but a similar side effect profile.
• Lenvatinib’s superior efficacy vs sorafenib regarding the secondary end points progression-free survival, time to
progression and overall response rate is clinically relevant.
• Sorafenib has been widely established and investigated in clinical practice, especially in patients with Child–Pugh
B cirrhosis.
• Comorbidities, side effect profiles, routes of administration and patient preferences need to be taken into
account when choosing treatment.
Second-line treatment
• Patient selection, among other factors, is based on the reason for discontinuation of first-line sorafenib
(intolerance or progression).
• Regorafenib’s efficacy in patients unable to tolerate sorafenib has not been studied.
• Alpha fetoprotein levels are a prognostic biomarker as well as a predictive biomarker for ramucirumab treatment.
• Ramucirumab has a favorable tolerability profile.
• Cabozantinib’s efficacy has been demonstrated in both second-line and third-line treatment.
• Whichever second-line treatment is chosen, effective blood pressure control and/or monitoring is required for all
patients.
Sequential therapy
• All the currently approved second-line treatments have been investigated in patients progressing on or becoming
intolerant to prior sorafenib.
• At present, no data are available for treatment sequences following first-line atezolizumab plus bevacizumab or
following first-line lenvatinib.
• The only current treatment option not approved according to treatment line is sorafenib; however, second-line
efficacy of the TKI has not been demonstrated in a prospective trial.
• To generate more evidence, subsequent therapies will need to be included in current first-line studies and
dedicated sequence studies will need to be initiated.
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